Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-BCMA AlloCAR T
- Development stage
- Unknown
- Lead developer
- Allogene Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anti-BCMA AlloCAR T refers to a suite of allogeneic chimeric antigen receptor (CAR) T-cell therapies developed by Allogene Therapeutics that target B-cell maturation antigen (BCMA). Unlike autologous CAR T therapies, which use a patient's own cells, these 'off-the-shelf' products are derived from healthy donor T-cells. The platform utilizes TALEN gene-editing technology to disrupt the T-cell receptor (TCR) alpha constant (TRAC) gene to reduce the risk of graft-versus-host disease (GvHD) and the CD52 gene to allow for selective lymphodepletion. Specific candidates include ALLO-715 and ALLO-605, the latter being a 'TurboCAR' variant designed to enhance T-cell activation and persistence. These therapies are primarily being developed for the treatment of relapsed or refractory multiple myeloma.
- Other names
- BCMA AlloCAR TAllogeneic BCMA CAR-T
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on anti-BCMA AlloCAR T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-BCMA AlloCAR T.